# US 2019/0316201 A1 · Differential diagnosis of eczema and psoriasis > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2019/0316201 A1 - Document ID: US20190316201A1 - Status: Published application - Kind: A1 - Application number: 16/428,411 - Filed: 2019-05-31 - Published: 2019-10-17 - Earliest claimed: 2014-04-15 - Assignees: Helmholtz Zentrum MüNchen - Deutsches Forschungszentrum FüR Gesundheit Und Umwel; Klinikum Rechts Der Isar Der Technischen UniversitäT MüNchen - Applicants: Helmholtz Zentrum MüNchen - Deutsches Forschungszentrum FüR Gesundheit Und Umwel; Klinikum Rechts Der Isar Der Technischen UniversitäT MüNchen - Inventors: Kilian EYERICH; Carsten SCHMIDT-WEBER; Bettina KNAPP - Web page: https://patentgrep.com/patent/US20190316201A1 ## CPC - C12Q 1/6883: for diseases caused by alterations of genetic material - C07K 16/24: against cytokines, lymphokines or interferons - C07K 16/40: against enzymes - G01N 33/6881: {from skin} - C07K 16/18: against material from animals or humans - C07K 16/22: against growth factors {; against growth regulators} - C07K 16/244: {Interleukins [IL]} - C07K 16/2866: {against receptors for cytokines, lymphokines, interferons} - C12Q 2600/112: Disease subtyping, staging or classification - C12Q 2600/158: Expression markers - C12Q 2600/16: Primer sets for multiplex assays - G01N 2800/205: Scaling palpular diseases, e.g. psoriasis, pytiriasis - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The present invention relates to a method of diagnosing eczema and/or psoriasis, wherein said method differentiates between eczema and psoriasis, and comprises determining the expression of at least two markers in a sample taken from an individual, wherein said at least two markers are selected from CCL27, NOS2, IL36G, KLK13, SOST, NPTX1, PLA2G4D, GDA, IL36A, TGM1, CLEC4G, IL13, TCN1, TMPRSS11D and RHCG, provided that said at least two markers consist of or comprise (a) CCL27 and NOS2; (b) CCL27 and KLK13; (c) IL36G and KLK13; (d) CCL27 and IL36G; (e) NOS2 and IL36G; (f) NOS2 and KLK13; (g) SOST; or (h) NPTX1; and assessing on the basis of the expression of said at least two markers whether the individual is afflicted with eczema and/or psoriasis. ## Claims ### Claim 1 A kit comprising means for quantifying the expression of at least two genes selected from CCL27, NOS2, IL36G, KLK13, SOST, NPTX1, PLA2G4D, GDA, IL36A, TGM1, CLEC4G, IL13, TCN1, TMPRSS11D and RHCG, provided that said at least two genes include at least one of sets (a) to (h): (a) CCL27 and NOS2; (b) CCL27 and KLK13; (c) IL36G and KLK13; (d) CCL27 and IL36G; (e) NOS2 and IL36G; (f) NOS2 and KLK13; (g) SOST; or (h) NPTX1. ### Claim 2 (depends on 1) The kit of claim 1, wherein said at least two genes include CCL27 and NOS2. ### Claim 3 (depends on 1) The kit of claim 1, wherein said at least two genes are only CCL27 and NOS2. ### Claim 4 (depends on 1) The kit of claim 1, wherein said means are primers that specifically bind to nucleic acids of said genes. ### Claim 5 (depends on 2) The kit of claim 2, wherein said means are primers that specifically bind to nucleic acids of said genes. ### Claim 6 (depends on 4) The kit of claim 4, wherein the primers that specifically bind to nucleic acids of said genes are pairs of primers, and: the primers that specifically bind to nucleic acids of CCL27 have the nucleotide sequences of SEQ ID NOs: 1 and 2; the primers that specifically bind to nucleic acids of NOS2 have the nucleotide sequences of SEQ ID NOs: 3 and 4; the primers that specifically bind to nucleic acids of IL36G have the nucleotide sequences of SEQ ID NOs: 5 and 6; the primers that specifically bind to nucleic acids of KLK13 have the nucleotide sequences of SEQ ID NOs: 7 and 8; the primers that specifically bind to nucleic acids of SOST have the nucleotide sequences of SEQ ID NOs: 9 and 10; the primers that specifically bind to nucleic acids of NPTX1 have the nucleotide sequences of SEQ ID NOs: 11 and 12; the primers that specifically bind to nucleic acids of PLA2G4D have the nucleotide sequences of SEQ ID NOs: 13 and 14; the primers that specifically bind to nucleic acids of GDA have the nucleotide sequences of SEQ ID NOs: 15 and 16; the primers that specifically bind to nucleic acids of IL36A have the nucleotide sequences of SEQ ID NOs: 17 and 18; the primers that specifically bind to nucleic acids of TGM1 have the nucleotide sequences of SEQ ID NOs: 19 and 20; the primers that specifically bind to nucleic acids of CLEC4G have the nucleotide sequences of SEQ ID NOs: 21 and 22; the primers that specifically bind to nucleic acids of IL13 have the nucleotide sequences of SEQ ID NOs: 23 and 24; the primers that specifically bind to nucleic acids of TCN1 have the nucleotide sequences of SEQ ID NOs: 25 and 26; the primers that specifically bind to nucleic acids of TMPRSS11D have the nucleotide sequences of SEQ ID NOs: 27 and 28; the primers that specifically bind to nucleic acids of RHCG have the nucleotide sequences of SEQ ID NOs: 29 and 30. ### Claim 7 (depends on 5) The kit of claim 5, wherein the primers that specifically bind to nucleic acids of said genes are pairs of primers, and: the primers that specifically bind to nucleic acids of CCL27 have the nucleotide sequences of SEQ ID NOs: 1 and 2; the primers that specifically bind to nucleic acids of NOS2 have the nucleotide sequences of SEQ ID NOs: 3 and 4. ### Claim 8 (depends on 1) The kit of claim 1, wherein said means are antibodies that specifically bind to a protein expressed from said genes. ### Claim 9 (depends on 2) The kit of claim 2, wherein said means are antibodies that specifically bind to a protein expressed from said genes. ### Claim 10 (depends on 3) The kit of claim 3, wherein said means are antibodies that specifically bind to a protein expressed from said genes. ### Claim 11 (depends on 8) The kit of claim 8, wherein said antibodies that specifically bind the protein are monoclonal antibodies. ### Claim 12 (depends on 8) The kit of claim 8, wherein said antibodies that specifically bind the protein are polyclonal antibodies. ### Claim 13 (depends on 9) The kit of claim 9, wherein said antibodies that specifically bind the protein are monoclonal antibodies. ### Claim 14 (depends on 9) The kit of claim 9, wherein said antibodies that specifically bind the protein are polyclonal antibodies.